Bayer Forecasts Flat 2026 Profits Amid Roundup Settlement Effort
Bayer anticipates stable 2026 profits despite challenges from generic competition and ongoing Roundup litigation.Summary
Bayer AG projected minimal growth in both profit and sales for 2026, citing generic competition for its Xarelto blood thinner and continued legal uncertainties surrounding claims related to its Roundup weed killer. The company forecasts adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) to fall between €9.6 billion and €10.1 billion, slightly below analyst expectations of €9.75 billion. This projection follows a decline to €9.67 billion in the previous year. The news led to a drop in Bayer’s share price, reflecting investor concerns about the company’s ability to overcome these challenges and achieve significant growth in the near future. Bayer is actively working to resolve the Roundup litigation, which involves numerous lawsuits alleging the herbicide causes cancer.
(Source：Bloomberg)